This page contains a Flash digital edition of a book.
48 BIOTECHNOLOGY


Drug candidates hold promise for HIV drugs market


Patients to benefit from potential for improved efficacy in less commonly used types of antiretroviral therapies and one-pill-daily combination drugs.


Les patients devraient bénéficier du potentiel résultant de l’augmentation d’efficacité pour des types de thérapies antirétrovirales moins fréquemment appliquées et de médicaments combinés dans un seul comprimé par jour.


Patienten profitieren vom Potential für die verbesserte Effizienz der weniger häufig verwendeten antiretroviralen Therapiearten und Kombinationsmedikamente in einer Einzeltablette pro Tag.


T


$5.58 billion in 2012 and estimates this to reach $9.24 billion in 2019.


Te research covers the most actively used antiretroviral (ARV) therapies: nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitors, and other therapeutics (ARV compounds like CCR5 receptor antagonists, fusion inhibitors, maturation inhibitors, attachment inhibitors and PK boosters).


he anticipated launch of drugs currently in the pipeline, together with the


introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market.


New analysis from Frost & Sullivan, Analysis of the European HIV Drugs Market, finds that the market earned


“In addition to popularly existing therapies like NRTI, NNRTI, PI and integrase inhibitors, new drug candidates over the last decade have spurred the HIV drugs market,” says Frost & Sullivan Healthcare Research Analyst Deepika Pramod Chopda. “Te development of new candidates, derived from the less commonly used types of


ARV therapies like PK boosters, maturation inhibitors, and attachment inhibitors, is driving the overall market.”


With technically advanced features like easy consumption and higher adherence to combination therapy, these candidates assist highly active antiretroviral therapies (HAART), which are a combination of three or four types of ARV therapies. Teir value-added features and improved efficacy are expected to boost the prospects of less common drug types.


Te introduction of one-pill- daily combination drugs will also be a key factor in market development. A reduction in the number of drugs that need to be consumed directly reduces patient expenditure levels. Other advantages include convenience and ease of consumption.


Tis trend is poised to have a steady impact on the growth of the HIV drugs market. It is also likely to shift the focus from syringes, as a source of drug administration, to directly consumable pills.


A major restraint to market expansion remains poor compliance rates due to the absence of established treatment procedures. Tis can be offset by improving access to disease awareness campaigns, treatment guidelines, counselling sessions and targeted diagnostics from health governing bodies.


“Awareness building efforts related to HIV prevention among high-risk groups is increasing,” concludes Chopda. “Better understanding about the need to practice safe-sex, use sterilised needles and conduct blood transfusion in a sterile


www.scientistlive.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52